Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase NA 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 5 Drug-Related Side Effects and Adverse Reactions 2 Colorectal Neoplasms 2 Advanced Gastric Cancer 2 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Quality of Life 1 Peritoneal Metastases From Gastric Cancer 1 Ovarian Cancer Recurrent 1 Osteosarcoma 1 Meningioma 1 Immune Checkpoint Inhibition 1 Gastrointestinal Stromal Tumors 1 Esophageal Neoplasms 1 Chondrosarcoma 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Gastric Adenocarcinoma 1

Interventions

Fluorodeoxyglucose F18 4 Drug Therapy 2 nimotuzumab 1 apatinib 1 Ultrasonography, Doppler 1 Ultrasonography 1 Sirolimus 1 Re-Irradiation 1 Radiosurgery 1 RE1-silencing transcription factor 1 Proton Therapy 1 Ink 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase NA × Solid Tumor × apatinib × Clear all

NCT05380986 2022-05-19

Camrelizumab Combined With Apatinib Mesylate

Henan Cancer Hospital

Phase NA Unknown

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡